Depending on the Phase I trials’ outcomes, Spyre plans to advance the SPY002 programme into Phase II development next year.

A new study published in the journal of Inflammatory Bowel Disorder showed that children with inflammatory bowel disease (IBD ...

The U.S. biotech company Spyre Therapeutics announced yesterday that it has dosed the first participants in two Phase 1 ...

Sanjay K. Murthy, MD, MSc (Epid), talked with Physician’s Weekly about changes in digestive cancer types among patients with ...

Presentations at the 2024 Asembia Specialty Pharmacy Summit focused on reshaping specialty pharmacy while keeping patients ...

Chronic diarrhea can be a frustrating and exhausting condition. It’s more than just an inconvenience—it can seriously affect ...

A new study from The Hospital for Sick Children (SickKids) and Institut Curie reveals how stem cells sense and respond to their environment, with implications for inflammatory bowel disease and ...

Factors portending the greatest risk for cardiovascular death in control patients were inflammation (baseline plasma high-sensitivity C-reactive protein ≥2 mg/L; p=0.003) and ischemic HFrEF etiology ...

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

We think UCB is in good financial health, with solid earnings and cash flow generation. UCB has deleveraged over the years, and it ended 2023 with about EUR 2.2 billion in net debt on its balance ...

A new study from The Hospital for Sick Children (SickKids) and Institut Curie reveals how stem cells sense and respond to ...